文献速递淋巴瘤

莫格利珠单抗耐药与皮肤T细胞淋巴瘤中CCR4缺失相关

Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.
PubMed 文献 · Blood · 2022-01-01

莫格利珠单抗是靶向CCR4的人源化抗体,用于治疗蕈样肉芽肿和Sézary综合征。研究分析17例对莫格利珠单抗原发或继发耐药的患者,发现65%的患者CCR4低表达,3例疾病进展后出现新的CCR4突变,2例伴CCR4突变的患者出现拷贝数丢失,且CCR4基因组改变与抗原表达缺失对应。

要点

  • 莫格利珠单抗耐药患者的CCR4低表达率为65%。
  • 疾病进展后可出现新的CCR4突变,累及N端和跨膜结构域。
  • CCR4基因组改变与CCR4抗原表达缺失相对应。

核心结论

  • 皮肤T细胞淋巴瘤对莫格利珠单抗耐药常涉及CCR4表达缺失和CCR4基因组改变的出现。

研究设计与样本

  • 研究纳入17例对莫格利珠单抗原发耐药或继发耐药的蕈样肉芽肿或Sézary综合征患者。

主要发现

  • 免疫组化或流式细胞术检测显示65%的患者CCR4低表达。
  • 3例患者在疾病进展后发现累及N端和跨膜结构域的新发CCR4突变。
  • 2例携带CCR4突变的患者检测到新出现的CCR4拷贝数丢失。
  • CCR4基因组改变的出现与CCR4抗原表达缺失相对应。

关键数值与推荐

  • 65%的患者(17例中)经免疫组化或流式细胞术检测为CCR4低表达。
  • 3例患者疾病进展后发现新发CCR4突变,累及N端和跨膜结构域。
  • 2例携带CCR4突变的患者检测到新出现的CCR4拷贝数丢失。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mogamulizumab is a humanized anti-CC chemokine receptor 4 (CCR4) antibody approved for the treatment of mycosis fungoides and Sézary syndrome. Despite almost universal expression of CCR4 in these diseases, most patients eventually develop resistance to mogamulizumab. We tested whether resistance to mogamulizumab is associated with loss of CCR4 expression. We identified 17 patients with mycosis fungoides or Sézary syndrome who either were intrinsically resistant or acquired resistance to mogamulizumab. Low expression of CCR4 by immunohistochemistry or flow cytometry was found in 65% of patients. Novel emergent CCR4 mutations targeting the N-terminal and transmembrane domains were found in 3 patients after disease progression. Emerging CCR4 copy number loss was detected in 2 patients with CCR4 mutations. Acquisition of CCR4 genomic alterations corresponded with loss of CCR4 antigen expression. We also report on outcomes of 3 cutaneous T-cell lymphoma (CTCL) patients with gain-of-function CCR4 mutations treated with mogamulizumab. Our study indicates that resistance to mogamulizumab in CTCL frequently involves loss of CCR4 expression and emergence of CCR4 genomic alterations. This finding has implications for management and monitoring of CTCL patients on mogamulizumab and development of future CCR4-directed therapies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Beygi S, Duran GE, Fernandez-Pol S, et al. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma. Blood. 2022. PMID: 35436328. doi:10.1182/blood.2021014468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。